Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization - TARGET

Description:

The Do Tirofiban and ReoPro Give Similar Efficacy Trial (TARGET) was a double-blind, double-dummy, multicenter, international, prospective, randomized trial designed to compare the safety and efficacy between two glycoprotein (GP) IIb/IIIa inhibitors, tirofiban and abciximab, in the setting of percutaneous coronary revascularization.